104
Participants
Start Date
December 15, 2024
Primary Completion Date
December 15, 2027
Study Completion Date
December 15, 2027
Insulin resistance testing
Steady state Plasma Glucose test
OGTT
Will collect 5 blood draws during the test to measure insulin secretion
Fat biopsy
Needle biopsy to gather a sample of abdominal subcutaneous fat
DXA scan
Whole body DXA scan
MRI
Abdominal MRI
1H-MRS
Spectroscopy of the abdominal region
Tirzepatide
16 weeks started at 2.5mg/week and increased to 5mg/week dose
Pioglitazone
16 weeks at a 45mg/day dose
Stanford University, Clinical and Translational Research Unit (CTRU), Stanford
Stanford University
OTHER